Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioCryst Pharmaceuticals Inc BCRX

Healthcare Biotechnology
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.


NDAQ:BCRX - Post by User

BioCryst Pharmaceuticals Inc > BioCryst Shares Surged 35% After Hours on Thursday
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(470)
•••
Post by davgroon Apr 11, 2020 11:15am
175 Views
Post# 30898832

BioCryst Shares Surged 35% After Hours on Thursday

BioCryst Shares Surged 35% After Hours on Thursday

BioCryst stock rallies on start of coronavirus drug study


BioCryst Pharmaceuticals Inc. BCRX, +3.50% shares rallied in the extended session Thursday after the drug maker said it was starting a clinical trial to test its COVID-19 treatment. BioCryst shares surged 35% after hours, following a 3.5% rise to close the regular session at $2.07. The company said it opened a randomized, double-blind, placebo-controlled clinical trial to test the drug galidesivir in treating patients with COVID-19. The study, which is being funded by the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases, will be conducted in Brazil, the company said. Many drug companies have recently started development of either COVID-19 treatments or vaccines.

https://www.marketwatch.com/story/biocryst-stock-rallies-on-start-of-coronavirus-drug-study-2020-04-09

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities